NEXI
NexImmune, Inc.Company Information
- Company Name
- NexImmune, Inc.
- CIK
- CIK0001538210
- Category
- <br>Emerging growth company
- Ticker: Exchange
- NEXI: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NEXI
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-06-11
- Last sale
- 2023-11-22
- Shares purchased (TTM)
- 1
- Shares sold (TTM)
- 3,992
Institutional Sentiment
- As of
- 2024-09-30
- Institutional shares owned
- 10,804
- Shares outstanding
- 1,380,395
- Ownership
- 0.78%
Earnings Market Reaction
- Filing date
- 2024-08-07
- Price on filing date
- —
- 1-month reaction
- -59.82%
- 3-month reaction
- -80.57%
Balance Sheet
Values in millions ($)| Line item | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 4 | 3 | 9 | 16 | 22 | 35 | 46 | 41 | 25 | 30 | 37 | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | 0 | 0 | 12 | 41 | 51 | 56 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Held For Sale Long Lived Fair Value Disclosure | 0 | 1 | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 6 | 6 | 7 | 4 | 5 | ||||||
| Assets Current | 3 | 6 | 5 | 10 | 19 | 25 | 37 | 52 | 60 | 72 | 86 | 99 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 4 | 4 | 4 | 4 | 5 | 5 | 4 | 4 | 4 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | - | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | ||||||
| Assets | 6 | 9 | 9 | 15 | 23 | 31 | 43 | 58 | 66 | 78 | 91 | 105 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 4 | ||||||
| Accrued Liabilities Current | 3 | 4 | 4 | 5 | 5 | 6 | 7 | 8 | 7 | 4 | 6 | 4 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | - | ||||||
| Liabilities Current | 5 | 5 | 5 | 6 | 6 | 7 | 10 | 9 | 9 | 7 | 7 | 7 | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | - | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Deferred Rent Credit Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Due To Related Parties Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | 0 | 1 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 5 | 6 | 5 | 6 | 6 | 7 | 11 | 10 | 10 | 8 | 7 | 7 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | 0 | 0 | - | - | 0 | 0 | - | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 229 | 228 | 226 | 225 | 224 | 223 | 223 | 221 | 214 | 213 | 211 | 209 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -228 | -226 | -223 | -217 | -207 | -200 | -190 | -173 | -159 | -143 | -128 | -112 | ||||||
| Stockholders Equity | 1 | 3 | 4 | 8 | 17 | 24 | 32 | 48 | 56 | 70 | 84 | 97 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | 0 | 0 | -0 | -0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 6 | 9 | 9 | 15 | 23 | 31 | 43 | 58 | 66 | 78 | 91 | 105 | ||||||
| Redeemable Noncontrolling Interest Equity Preferred Carrying Amount | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | - | - | - | - | - | - | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 0 | - | - | - | - | - | - | - | - | - | 10 | - | ||||||
| Preferred Stock Shares Issued | 0 | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
Common Stock Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Series A Redeemable Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Series A Two Redeemable Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Series A Three Redeemable Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Preferred Stock Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Subsequent Event | - | - | - | 1 | - | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNexImmune, Inc. (NEXI) — SEC Financial Statements & Analysis
NexImmune, Inc. (NEXI) is a pharmaceutical preparations company, incorporated in DE. NexImmune, Inc. trades on OTC as: NEXI. NexImmune, Inc. (NEXI)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-07. Based on that filing, NexImmune, Inc. carries a market cap of $3.81M, a P/E ratio of -0.18x, a P/B ratio of 5.47x, an enterprise value of $1.37M, and an EV/EBITDA multiple of -0.07x. On profitability, it posts a Return on Equity (ROE) of -232.97%, a Return on Assets (ROA) of -140.56%, and a Return on Invested Capital (ROIC) of -630.48%. Per share, it reports EPS of $-14.94, diluted EPS of $-14.94, free cash flow per share of $-12.75, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -57.71% year-over-year and EPS growth of -68.04% year-over-year. On the balance sheet, it maintains a current ratio of 0.66x, a quick ratio of 0.55x, working capital of $-1.61M, a debt-to-equity ratio of 7.10x, a debt ratio of 0.84, an interest coverage ratio of -56059.72x, free cash flow of $-17.61M (TTM), and net debt of $-2.44M. Figures sourced from SEC EDGAR.
- Market Cap
- $3.81M
- P/E TTM
- -0.18x
- EPS TTM
- $-14.94
- P/B TTM
- 5.47x
- ROE TTM
- -232.97%
- ROA TTM
- -140.56%
- Debt To Equity
- 7.10x
- Free Cash Flow TTM
- $-17.61M
Data as of 2024-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is NexImmune, Inc. in?
NexImmune, Inc. (NEXI) operates in the Pharmaceutical Preparations industry.
What exchange does NEXI trade on?
NexImmune, Inc. (NEXI) trades on the OTC.
Where is NexImmune, Inc. incorporated?
NexImmune, Inc. is incorporated in DE.
When was NexImmune, Inc. (NEXI)'s most recent SEC filing?
NexImmune, Inc. (NEXI)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-07.
What is NEXI's market cap?
NexImmune, Inc. (NEXI) has a market capitalization of $3.81M as of 2024-06-30.
What is NEXI's EPS (earnings per share)?
NexImmune, Inc. (NEXI)'s trailing twelve month EPS is $-14.94 as of 2024-06-30.
What is NEXI's ROE (return on equity)?
NexImmune, Inc. (NEXI)'s trailing twelve month Return on Equity (ROE) is -232.97% as of 2024-06-30.
What is NEXI's ROA (return on assets)?
NexImmune, Inc. (NEXI)'s trailing twelve month Return on Assets (ROA) is -140.56% as of 2024-06-30.
What is NEXI's ROIC (return on invested capital)?
NexImmune, Inc. (NEXI)'s trailing twelve month Return on Invested Capital (ROIC) is -630.48% as of 2023-06-30.
What is NEXI's EV/EBITDA?
NexImmune, Inc. (NEXI)'s trailing twelve month EV/EBITDA is -0.07x as of 2024-06-30.